Cargando…

Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study

BACKGROUND: Although patients with type 2 diabetes mellitus (T2DM) may fail to achieve adequate hemoglobin A1c (HbA1c) control despite metformin-sulfonylurea (Met-SU) dual therapy, a third-line glucose-lowering medication—including dipeptidyl peptidase-4 inhibitor (DPP4i), insulin, or thiazolidinedi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wong, Carlos K. H., Man, Kenneth K. C., Shi, Margaret, Chan, Esther W., Ho, Chu Wa, Tse, Emily T. Y., Wong, Ian C. K., Lam, Cindy L. K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6932752/ https://www.ncbi.nlm.nih.gov/pubmed/31877127 http://dx.doi.org/10.1371/journal.pmed.1002999

Ejemplares similares

DPP4i, thiazolidinediones, or insulin and risks of cancer in patients with type 2 diabetes mellitus on metformin–sulfonylurea dual therapy with inadequate control
por: Wong, Carlos K H, et al.
Publicado: (2020)

Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes
por: Kwon, Christina S., et al.
Publicado: (2018)

Treatment progression in sulfonylurea and dipeptidyl peptidase-4 inhibitor cohorts of type 2 diabetes patients on metformin
por: Peng, Xiaomei, et al.
Publicado: (2016)

Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin
por: Kim, Ye An, et al.
Publicado: (2015)

Dipeptidyl peptidase‐4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?
por: Yabe, Daisuke, et al.
Publicado: (2014)

Association of Hemoglobin A(1c) Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative
por: Vashisht, Rohit, et al.
Publicado: (2018)

Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study
por: Kim, Kyoung Jin, et al.
Publicado: (2019)

Review of the Case Reports on Metformin, Sulfonylurea, and Thiazolidinedione Therapies in Type 2 Diabetes Mellitus Patients
por: Susilawati, Elis, et al.
Publicado: (2023)

Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes
por: Gamble, John-Michael, et al.
Publicado: (2018)

Differential Cardiovascular Outcomes after Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Pioglitazone Therapy, All in Combination with Metformin, for Type 2 Diabetes: A Population-Based Cohort Study
por: Seong, Jong-Mi, et al.
Publicado: (2015)

Comparing treatment intensification and clinical outcomes of metformin and dipeptidyl peptidase‐4 inhibitors in treatment‐naïve patients with type 2 diabetes in Japan
por: Horii, Takeshi, et al.
Publicado: (2019)

Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients
por: Wang, Fei, et al.
Publicado: (2017)

Polyalthia Clerodane Diterpene Potentiates Hypoglycemia via Inhibition of Dipeptidyl Peptidase 4
por: Huang, Po-Kai, et al.
Publicado: (2019)

Natural phenolic compounds potentiate hypoglycemia via inhibition of Dipeptidyl peptidase IV
por: Huang, Po-Kai, et al.
Publicado: (2019)

Urinary exosomal microRNA profiling in type 2 diabetes patients taking dipeptidyl peptidase-4 inhibitor compared with sulfonylurea
por: Cho, Nam-Jun, et al.
Publicado: (2021)

Electronic medical records-based comparison of glycemic control efficacy between sulfonylureas and dipeptidyl peptidase-4 inhibitors added on to metformin monotherapy in patients with type 2 diabetes
por: Lee, Suhrin, et al.
Publicado: (2020)

Dynamics of total volume of pancreatic α‐ and β ‐cells under the influence sulfonylureas and their combination with dipeptidyl peptidase‐4 inhibitors
por: Taisiia Pavlovna, Tuchina, et al.
Publicado: (2021)

Combination Therapy with a Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Metformin Markedly Improves HbA(1c) Levels in Japanese Patients with Type 2 Diabetes Mellitus
por: Hirao, Koichi, et al.
Publicado: (2012)

Real-world comparison of mono and dual combination therapies of metformin, sulfonylurea, and dipeptidyl peptidase-4 inhibitors using a common data model: A retrospective observational study
por: Lee, Kyung Ae, et al.
Publicado: (2022)

Role of Octreotide in Sulfonylurea-Induced Hypoglycemia
por: Zafar, Sheema, et al.
Publicado: (2021)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Pharmacogenetics of Hypoglycemia Associated with Sulfonylurea Therapy in Usual Clinical Care
por: Mitchell, Sabrina L, et al.
Publicado: (2020)

Within-Sulfonylurea-Class Evaluation of Time to Intensification with Insulin (ZODIAC-43)
por: Schrijnders, Dennis, et al.
Publicado: (2016)

Effects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor γ Activity and on Glucose Uptake by Thiazolidinediones
por: Lee, Kyeong Won, et al.
Publicado: (2011)

Sulfonylurea-Induced Hypoglycemia in a Patient With Cirrhosis
por: Braet, Corey, et al.
Publicado: (2020)

Stress Cardiomyopathy Induced by Refractory Hypoglycemia Due to Acute Sulfonylurea Intoxication
por: Shah, Binoy K, et al.
Publicado: (2023)

Investigation of a Dipeptidyl Peptidase-4 Inhibitor/Thiazolidinedione Combination Drug for Patients With Type 2 Diabetes and Poor Glycemic Control: Difficulty With Patient Enrollment
por: Okamura, Keisuke, et al.
Publicado: (2019)

Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia: A nested case-control analysis
por: Bodmer, Michael, et al.
Publicado: (2008)

Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis
por: Jeon, Won Kyeong, et al.
Publicado: (2021)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Evolutionary Analysis of Dipeptidyl Peptidase I
por: Varda, Nina, et al.
Publicado: (2022)

Optimizing the treatment of newly diagnosed type 2 diabetes mellitus with combination of dipeptidyl peptidase-4 inhibitors and metformin: An expert opinion
por: Das, Ashok K., et al.
Publicado: (2021)

Correction to: “Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysis”
por: Jeon, Won Kyeong, et al.
Publicado: (2022)

Systematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitors
por: Alanazi, Abdulrahman S.
Publicado: (2015)

Incident heart failure and myocardial infarction in sodium‐glucose cotransporter‐2 vs. dipeptidyl peptidase‐4 inhibitor users
por: Zhou, Jiandong, et al.
Publicado: (2022)

Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors Versus Sulfonylureas as the First Add-On to Metformin Monotherapy: A Retrospective Cohort Study
por: Roberto, Giuseppe, et al.
Publicado: (2022)

Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and β-Cell Function in Type 2 Diabetes Mellitus: A Propensity Score-Matched Analysis
por: Bae, Jaehyun, et al.
Publicado: (2018)

Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment
por: Florentin, Matilda, et al.
Publicado: (2022)

The effect of metformin and thiazolidinedione use on lung cancer in diabetics
por: Mazzone, Peter J, et al.
Publicado: (2012)

Concurrent Use of Oral Anticoagulants and Sulfonylureas in Individuals With Type 2 Diabetes and Risk of Hypoglycemia: A UK Population-Based Cohort Study
por: Alwafi, Hassan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a8hvqrm850lu8r5ankcv1jrdld